Citi Pharma Ltd. has released its quarterly report for the period ended September 30, 2026, detailing its financial performance and position.
- Net sales for the quarter were PKR 3,363.5M, a slight decrease of 0.2% compared to PKR 3,370.2M in the same quarter last year.
- Gross profit increased by 20.6% to PKR 626.0M, with a gross profit margin improvement to 18.6% from 15.4%.
- Operating profit rose by 14.6% to PKR 481.6M, up from PKR 420.4M year-on-year.
- Profit before income tax increased by 21.3% to PKR 366.7M, leading to a net profit after tax of PKR 233.2M, a 14.5% increase from PKR 203.7M.
- Earnings per share (EPS) for the quarter was PKR 1.02, compared to PKR 0.89 in the previous year.
- Total assets as of September 30, 2026, were PKR 17,722.3M, down from PKR 18,119.6M as of June 30, 2026.
- Cash and bank balances stood at PKR 268.2M, with net cash generated from operating activities during the quarter at PKR 70.7M, a significant recovery from net cash used of PKR 463.7M in the same period last year.
- The report is un-audited and reflects a cautious outlook amid stable sales and improved profitability metrics.